Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14787210.3.2.201PMID 15918778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enteroaggregative Escherichia coli: An Emerging Enteric Pathogen

  2004cited by this paper
• CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue

  2004cited by this paper
• Analysis of virulence factors in cases of enterococcal endocarditis.

  2004cited by this paper
• Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.

  2004cited by this paper
• Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.

  2004cited by this paper
• Novel Roles for the AIDA Adhesin from Diarrheagenic Escherichia coli: Cell Aggregation and Biofilm Formation

  2004cited by this paper
• Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis

  2003cited by this paper
• Diagnosis and management of pouchitis.

  2003cited by this paper
• Antimicrobials as Potential Adjunctive Agents in the Treatment of Biofilm Infection with Staphylococcus epidermidis

  2003cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cited by this paper
• Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas.

  2003cited by this paper
• Therapy of travelers’ diarrhea with rifaximin on various continents

  2003cited by this paper
• Penetration of Rifampin through Staphylococcus epidermidis Biofilms

  2002cited by this paper
• Crohn's disease

  2002cited by this paper
• Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease

  2002cited by this paper
• An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm.

  2002cited by this paper
• Inflammatory bowel disease.

  2002cited by this paper
• Review article: medical treatment of active Crohn's disease.

  2002cited by this paper
• A population-based estimate of the burden of diarrhoeal illness in the United States: FoodNet, 1996–7

  2002cited by this paper
• Medical treatment of active Crohn's disease

  2002cited by this paper
• In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.

  2001cited by this paper
• In Vitro Antimicrobial Susceptibility Testing of Bacterial Enteropathogens Causing Traveler's Diarrhea in Four Geographic Regions

  2001cited by this paper
• In Vitro Activity of Rifaximin against Enteropathogens Producing Traveler's Diarrhea

  2001cited by this paper
• Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms.

  2001cited by this paper
• Clostridium difficile--Associated diarrhea: A review.

  2001cited by this paper
• Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

  2001cited by this paper
• Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea.

  2001cited by this paper
• Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth

  2000cited by this paper
• In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration

  2000cited by this paper
• Intestinal bacterial overgrowth during chronic pancreatitis.

  1999cited by this paper
• Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

  1999cited by this paper
• Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis

  1999cited by this paper
• Food-related illness and death in the United States.

  1999cited by this paper
• Rifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers’ Diarrhea

  1998cited by this paper
• Rifaximin systemic absorption in patients with ulcerative colitis

  1998cited by this paper
• Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

  1997cited by this paper
• Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

  1995cited by this paper
• The susceptibility of Helicobacter pylori to the rifamycin, rifaximin.

  1995cited by this paper
• Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

  1994cited by this paper
• In vitro activity of rifaximin againstHelicobacter pylori

  1994cited by this paper
• Rifaximin in the treatment of chronic hepatic encephalopathy.

  1993cited by this paper
• Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

  1993cited by this paper
• Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

  1993cited by this paper
• Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

  1991cited by this paper
• Principles and practice of infectious disease

  1990cited by this paper
• Treatment of Small Intestine Bacterial Overgrowth with Rifaximin, a Non-Absorbable Rifamycin

  1988cited by this paper
• In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

  1987cited by this paper
• In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin.

  1986cited by this paper
• A non-absorbable rifamycin for treatment of hepatic encephalopathy.

  1985cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper
• [Crohn's disease].

  1967cited by this paper

• Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational study.

  2026cites this paper
• Challenges in the Investigation of Therapeutic Equivalence of Locally Applied/Locally Acting Drugs in the Gastrointestinal Tract: The Rifaximin Case

  2025cites this paper
• Cross‐Linking of Hydroxypropylcellulose With Flaxseed Rhamnogalacturonans Using Citric Acid Produces a Hemocompatible Biocomposite for pH‐Responsive Rifaximin Delivery

  2025cites this paper
• Microwave-Assisted Synthesis of Watercress-Derived N,S-Doped Carbon Dots for Sensitive Spectrofluorimetric Determination of Rifaximin Antibiotic: Greenness, Blueness, and Whiteness Assessment

  2025cites this paper
• Future Therapies of Hepatic Encephalopathy.

  2024cites this paper
• Synthesis of imidazole-fused nitrogen-bridgehead heterocycles catalysed by lipase and their antifungal and antimicrobial bioactivity

  2024cites this paper
• Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis

  2024cites this paper
• Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy

  2023cites this paper
• Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial

  2023cites this paper
• Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole

  2023cites this paper
• Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review

  2023cites this paper
• Rifaximin protects SH‐SY5Y neuronal cells from iron overload‐induced cytotoxicity via inhibiting STAT3/NF‐κB signaling

  2022cites this paper
• Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea

  2022cites this paper
• Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review

  2022cites this paper
• Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis

  2022cites this paper
• Inadequate practices for hepatic encephalopathy management in the inpatient setting

  2022cites this paper
• Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites

  2022cites this paper
• Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome

  2021cites this paper
• Deep Eutectic Solvent‐Mediated Regioselective Synthesis of Imidazoheterocycles

  2021cites this paper
• Synergistic combination of phytotherapeutics for infectious diseases

  2021cites this paper
• Role of non-absorbable oral antibiotics in bowel preparation for intracavitary brachytherapy: effects of rifaximin on rectal dosimetric parameters during vaginal cuff brachytherapy

  2021cites this paper
• Gut Homeostasis; Microbial Cross Talks in Health and Disease Management

  2021cites this paper
• Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review

  2020cites this paper
• COMPARISON OF RIFAXIMIN PLUS LACTULOSE WITH THE LACTULOSE ALONE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY

  2020cites this paper
• A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

  2020cites this paper
• Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics

  2019cites this paper
• Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding

  2018cites this paper
• Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

  2018cites this paper
• Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial

  2018cites this paper
• New therapies in Irritable Bowel Syndrome: what works and when

  2018cites this paper
• A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.

  2018cites this paper
• Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy

  2017cites this paper
• Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial.

  2017cites this paper
• Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection

  2017cites this paper
• The impact of rifaximin in the prevention of bacterial infections in cirrhosis.

  2017cites this paper
• New insights into the pathogenesis and treatment of irritable bowel syndrome.

  2017cites this paper
• Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis

  2017cites this paper
• A meta-analysis of the use of rifaximin to prevent travellers’ diarrhoea

  2017cites this paper
• Catalyst‐Free, Glycerol‐Assisted Facile Approach to Imidazole‐Fused Nitrogen‐Bridgehead Heterocycles

  2017cites this paper
• Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

  2017cites this paper
• Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics.

  2017cites this paper
• Role of Rifaximin for the Treatment of Hepatic Encephalopathy in Chronic Liver Disease

  2017cites this paper
• Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.

  2017cites this paper
• The Gastrointestinal Microbiome: A Review

  2017cites this paper
• Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea

  2016cites this paper
• Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

  2016cites this paper
• [Chronic diarrhea in the diabetic. A review of the literature].

  2016cites this paper
• Reflections on antibiotic resistance and what to do about it.

  2016cites this paper
• Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats

  2016cites this paper
• A Comparative Study to Determine the Fate of Arterial Blood Ammonia Level in Patients of Decompensated Chronic Liver Disease with Short Course ( 7 days ) Therapy with Rifaximin And Or Lactullose

  2016cites this paper
• Reflections on antibiotic resistance and what to do about it.

  2016cites this paper
• Postinfectious Hemolytic Uremic Syndrome

  2016cites this paper
• Reflexiones sobre la resistencia a antibióticos y qué hacer al respecto

  2016cites this paper
• The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.

  2015cites this paper
• Advances in cirrhosis: Optimizing the management of hepatic encephalopathy.

  2015cites this paper
• Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.

  2015cites this paper
• Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

  2015cites this paper
• Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

  2015cites this paper
• Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review

  2014cites this paper
• Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review.

  2014cites this paper
• Microbiota, infecciones gastrointestinales, inflamación de bajo grado y antibioticoterapia en el síndrome de intestino irritable. Una revisión basada en evidencias

  2014cites this paper
• Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.

  2014cites this paper
• A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

  2013cites this paper
• Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis

  2013cites this paper
• Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

  2013cites this paper
• Rifaximin in prevention and treatment of hepatic encephalopathy

  2013cites this paper
• Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

  2013cites this paper
• Pharmakologische Aspekte

  2013cites this paper
• Gastrointestinal complications of diabetes mellitus.

  2013cites this paper
• Hepatic encephalopathy.

  2012cites this paper
• A Current Review of the Diagnostic and Treatment Strategies of Hepatic Encephalopathy

  2012cites this paper
• Impact of rifaximin use for hepatic encephalopathy on the risk of early post‐transplant infections in liver transplant recipients

  2012influential citation
• Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori

  2012cites this paper
• Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

  2012cites this paper
• Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence

  2012cites this paper
• Management of overt hepatic encephalopathy.

  2012cites this paper
• Rifaximin for the treatment of irritable bowel syndrome

  2012cites this paper
• Rifaximin therapy for patients with irritable bowel syndrome without constipation.

  2011cites this paper
• Rifaximina para encefalopatía hepática en niños: Caso clínico

  2011cites this paper
• A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

  2011cites this paper
• Antibiotics for the treatment of irritable bowel syndrome.

  2011cites this paper
• Suppositoires contenant de la rifaximine

  2011cites this paper
• Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects

  2011cites this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cites this paper
• CHAPTER 27 – Rifamycins

  2010cites this paper
• Neurologic presentations of hepatic disease.

  2010cites this paper
• Rifaximin for the treatment of hepatic encephalopathy

  2010cites this paper
• Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells.

  2010cites this paper
• Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital

  2009cites this paper
• Rifaximin for Treatment of Hepatic Encephalopathy

  2009cites this paper
• A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Nonabsorbable Antibiotic, in the Treatment of Tropical Enteropathy

  2009cites this paper
• Rifaximin pharmacology and clinical implications

  2009cites this paper
• Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study

  2009cites this paper
• Trends in Clostridium difficile Disease: Epidemiology and Intervention.

  2009cites this paper
• Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials

  2009cites this paper
• Emerging Issues in Gastroenterology and Hepatology.

  2009cites this paper
• Emerging Therapies for the Treatment of Helicobacter pylori Infections

  2008cites this paper
• The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment

  2008cites this paper
• Nitazoxanide to treat persistent Clostridium difficile colitis.

  2008cites this paper
• Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?

  2008cites this paper